Biodexa shares surge 39.09% after-hours after enrolling first European patients in Phase 3 Serenta trial.

Biodexa Pharmaceuticals (BDRX) surged 39.09% in after-hours trading following the announcement that it enrolled the first European patients into its pivotal Phase 3 Serenta trial for fibrous adenomas (FAP). This milestone, reported by GlobeNewswire four days prior, marks progress in the company’s regulatory pathway, with the first European patient expected in 4Q 2025. Earlier, BDRX had activated its first European site for the trial and secured regulatory approval for the Phase 3 trial in Europe. These developments, highlighting clinical and operational advancements in a $7 billion target market, likely drove the sharp after-hours rally. Other news about European ADRs or unrelated stocks did not impact BDRX’s performance.